---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-109241"
form_type: "8-K"
ticker: null
cik: "0001567892"
company_name: "Keenova Therapeutics plc"
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:23:48.734966+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mallinckrodt completes spin-off of Par Health, renames as Keenova Therapeutics

## Summary
- Spin-off of Par Health (generic pharma and sterile injectables) completed Nov 10, 2025; Mallinckrodt renamed to Keenova Therapeutics.
- Par Health becomes an independent private company; no longer listed on any exchange.
- CVR agreement with Opioid Master Disbursement Trust II terminated for $35M payment.
- Keenova intends to list on NYSE in 2026 with a public offering; 2024 pro-forma revenue $1.7B, >1,600 employees.
- Leading products: Acthar Gel and XIAFLEX; focus on rare/unaddressed conditions across multiple therapeutic areas.

## SEC filing metadata
- accession: 0001104659-25-109241
- form_type: 8-K
- cik: 0001567892
- company_name: Keenova Therapeutics plc
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 1.02, 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567892/000110465925109241/0001104659-25-109241-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567892/000110465925109241/tm2530694d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-109241
- JSON: https://secwatch.observer/filing/0001104659-25-109241.json
- Plain text: https://secwatch.observer/filing/0001104659-25-109241.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.